What Arudol treats: main uses and benefits

Symptomatic Relief for Acute Abdominal and Visceral Cramping

Arudol is commonly used to help with symptom clusters that may become intense or disruptive within the gastrointestinal system and related organs. The medication is considered relevant for easing symptoms associated with functional disorders of the digestive tract and bile ducts.

Managing Discomfort in Urological and Gynecological Symptom Clusters

The medication is applied across domains where additional symptomatic support is needed to manage discomfort associated with certain organ-specific functional stress. The core indications for Arudol include acute, painful spasmodic disorders of the digestive tract and bile ducts, as well as acute spasmodic disorders of the urinary tract and gynecological systems, such as painful menstruation or conditions related to renal colic.

Arudol contributes to improved day-to-day comfort during periods of heightened symptoms. The medication helps ease the overall symptom load, particularly when symptoms create noticeable functional strain. It is relevant in clinical settings where supportive symptom management is appropriate, offering supportive relief when symptoms interfere with routine activities.

---

Quick Fact: Relief for Spasmodic Discomfort Arudol is relevant for easing acute symptoms that arise from spasmodic discomfort in internal organs, helping to manage sharp, sudden episodes of pain.

Regulatory References

1. Malta Medicines Authority regulatory document on Phloroglucinol

Eligibility Map: Who Can and Cannot Use Arudol

Arudol's eligibility profile is strictly defined by regulatory documents, which establish population groups for whom use is permitted, restricted, or contraindicated.

Classification	Populations
Absolute Contraindication	Patients with severe hepatic insufficiency, severe renal insufficiency, or cardiac insufficiency (specifically low output syndrome) must not use this medicine. Use is also prohibited in patients with known hypersensitivity to the active ingredient or excipients, or certain rare hereditary metabolic disorders (e.g., galactose intolerance).
Age-Related Status	Use is contraindicated in children below 6 years of age. Use in older children is permitted, but subject to specific maximum daily amount limitations.
Restricted or Conditional Use	The medicine is not recommended during breastfeeding due to a lack of adequate data. Use is generally avoided during pregnancy. Special caution is advised for elderly people, patients with hypotension (low blood pressure), and individuals with Parkinson's Disease.

---

Eligibility Classifications (High-Level)

Eligibility severity classification:

• Contraindicated: Applies to severe organ failure and children below 6 years of age.
• Not Recommended: Applies to women who are breastfeeding.
• Use with Caution: Applies to elderly patients and those with non-severe organ impairment.

Connection to the overall eligibility profile:

Regulatory documents define who can and cannot use Arudol by establishing strict absolute contraindications based on the severity of cardiac and organ function, requiring total exclusion for patients with specific severe conditions. Furthermore, regulators establish clear age limitations, prohibiting use below 6 years and applying restrictions to older pediatric patients. The official profile is completed by stating that use is not recommended for populations where safety data is limited, such as during breastfeeding.

The interaction profile for Drotaverine hydrochloride (Arudol) is defined by officially documented pharmacodynamic and pharmacokinetic interaction patterns, as detailed in regulatory prescribing information.

Pharmacodynamic Interactions

Co-administration with Levodopa is officially noted to decrease the antiparkinsonian effect of Levodopa, an outcome that may lead to an increase in patient rigidity and tremor. Conversely, concurrent use with other spasmolytic agents may result in an enhanced spasmolytic effect. Combining Arudol with agents that can lower blood pressure, such as Tricyclic Antidepressants, Quinidine, or Procainamide, is documented to increase the risk of hypotension. The spasmogenic activity caused by Morphine is officially inhibited by Drotaverine.

Exposure-Modifying and Substance Interactions

Certain substances are documented to alter the absorption or clearance profile. Magnesium Hydroxide may increase the absorption of Drotaverine. Co-administration with Lithium is officially associated with an increased risk of lithium toxicity. Separately, the concurrent consumption of alcohol is documented to increase the occurrence of dizziness. No mandatory timing-based separation rules or explicit drug-drug combination contraindications are noted in the regulatory interaction summaries.

How Arudol Works

---

Direct Musculotropic Action via PDE4 Enzyme Inhibition

The primary mechanism involves Drotaverine acting as a selective inhibitor of the Phosphodiesterase-4 (PDE4) enzyme. This targeted enzyme blockade prevents the hydrolysis of the cellular messenger cyclic AMP (cAMP), leading to its accumulation. The subsequent increase in cAMP activates Protein Kinase A (PKA), which then phosphorylates and inactivates Myosin Light Chain Kinase (MLCK), the enzyme required for muscle contraction.

Modulating Calcium Dynamics and Peripheral Selectivity

The PDE4-driven cascade promotes smooth muscle fiber relaxation independent of autonomic nerve input. Furthermore, the molecule can directly influence muscle excitability by acting as a non-competitive blocker of L-type Voltage-Dependent Calcium Channels (L-VOCCs), thereby limiting the influx of extracellular calcium (Ca^2+) necessary for contraction. This mechanism is exclusively peripheral, targeting smooth muscle tissue without penetrating the central nervous system, localizing the modulation of contractile activity.

Official Administration Guidelines for Arudol

Arudol, containing Drotaverine hydrochloride, is used according to specific administration and dosage rules, focusing strictly on how the medicine is taken, not why it is prescribed. The medication is available in two principal forms to support both outpatient and acute clinical settings.

---

Administration Scope and Dosing

Instruction	Official Rule
Route of administration	Oral route (for tablets); Intramuscular (IM) injection or Intravenous (IV) injection (for solution).
Dosing schedule (Adults)	Oral Dose Range: 120 mg to 240 mg total daily dose. Parenteral Dose: Typically 40 mg to 80 mg per single injection.
Frequency pattern	Oral: Administered in 2 to 3 divided doses daily. Parenteral: 1 to 3 times per day.
Intake Condition	The oral tablet is generally instructed to be taken with a full glass of water.

---

Population-Specific and Procedural Instructions

Official labeling includes specific restrictions for younger patients to ensure appropriate use. The maximum daily oral dose for children aged 6 to 12 years is limited to 80 mg, given in two divided doses. For children above 12 years, the maximum daily dose is 160 mg over 2 to 4 doses.

In cases where a dose is missed, the user should not take extra medicine to compensate, but rather continue the regular schedule. Furthermore, administration of the injectable solution, especially via the intravenous route, must occur as a slow injection and only under the supervision of a healthcare professional.

Arudol: Recent Clinical Evidence

Research has explored the use of Arudol (Drotaverine hydrochloride) in the symptomatic management of various conditions characterized by smooth muscle spasm and related physical discomfort.

Evidence for Gastrointestinal and Biliary Spasm

Studies for Irritable Bowel Syndrome (IBS) symptoms, a condition marked by fluctuating or episodic manifestations, have primarily been conducted as short-term Randomized Controlled Trials (RCTs). These trials monitored patient-reported outcomes for abdominal pain severity and changes in bowel function. Findings from these populations suggest patterns of measured change in pain severity during the study period. However, research into the long-term patterns of symptom change is limited, as follow-up durations were typically short (e.g., four weeks).

For acute episodes such as biliary colic, evidence largely relies on observational settings and clinical summaries. This data describes its pattern of use as a supportive agent during acute, disruptive episodes of heightened symptom activity. For general spasmodic abdominal pain, research highlights short-term changes measured in pain intensity after administration.

---

Evidence for Genitourinary and Gynecological Spasm

Arudol was evaluated in women experiencing painful menstruation (dysmenorrhea). Studies report patterns of measured changes in the severity of menstrual cramping. Similarly, the medicine was studied for its use in managing pain associated with renal colic (kidney stones), with data showing patterns related to short-term symptomatic relief during acute events.

In specialized settings, the medicine has been explored for its physiological effects in pregnant women, where researchers examined outcomes monitoring physiological strain on uterine blood flow. The findings generally reported patterns that included no significant measured effects on certain fetal circulation parameters, though certainty remains low for therapeutic recommendations in this context. Evidence is limited for pediatric populations, and subgroup findings are uncertain for specific conditions in older adults.

Key Studies & References

1. Study Details | NCT00292747 | Drotaverine in Dysmenorrhoea Treatment
2. Drotaverine to improve progression of labour among parturient women- a case control study

Common questions about Arudol (FAQ)

Q: When is the best time to take Arudol?

The product information often suggests taking this medication at a consistent time each day. For some formulations, taking it with a meal may be indicated to help with absorption or minimize stomach upset. Specific administration guidance should be based on your prescription label and the advice of your healthcare provider.

Q: What should I do if I miss a dose of Arudol?

If a dose is missed, it is generally advised to take it as soon as it is remembered. However, if it is close to the time for the next scheduled dose, the missed dose is usually skipped, and the regular schedule is continued. Do not take two doses to make up for a missed one. Consult your healthcare provider or pharmacist for guidance specific to your treatment plan.

Q: Can Arudol be stopped suddenly?

Stopping Arudol abruptly may not be advisable for certain treatment courses. Depending on the condition being treated, a gradual reduction in dosage (tapering) may be necessary to minimize the potential for withdrawal symptoms or a return of symptoms. Always discuss discontinuing or changing your dose with your prescribing physician.

Q: Does Arudol interact with common non-prescription medications?

Arudol may have interactions with various prescription and non-prescription products. It is important to inform your healthcare provider and pharmacist about all other medications, supplements, and herbal products you are taking. They can assess the risk of interaction and provide appropriate separation or monitoring advice.

How to Store and Dispose of Arudol (Drotaverine Hydrochloride)

Official regulatory documentation specifies strict storage and disposal requirements for Arudol, encompassing both the tablet and injection forms.

Storage Conditions

Product Form	Required Temperature	Environmental Protection
Tablets	Must not exceed 30, C	Protect from light and moisture, store in original carton
Injection Solution	Must be stored below 30, C	Protect from light; do not use if turbid or discoloured

The medicine, in all forms, must be stored out of the sight and reach of children. The tablets have a labeled shelf life of 36 months when these conditions are maintained.

Disposal Instructions

Unused or expired Arudol must not be disposed of via household trash or wastewater. Disposal is required to follow local environmental protection measures. Patients should consult their pharmacist for the correct method to discard the medicine.